Boehringer Ingelheim and BioMed X have successfully applied a crowdsourcing approach to establish a research team of outstanding scientists from around the world with bright ideas, who will endeavor to identify new approaches for the treatment of patients with chronic obstructive pulmonary disease (COPD).

Following the economic and legal separation of Covestro, Bayer is charting the course for its successful development as a Life Science company. On Friday, the Supervisory Board approved the reorganization proposed by the Board of Management. From January 1, 2016, the company’s business will be managed by three divisions: Pharmaceuticals, Consumer Health and Crop Science.

New research shows that the quality of patient-physician communication at diagnosis of type 2 diabetes (T2D) may impact future patient self-care and well-being.(1) Data from the IntroDia™ Survey, the largest international survey of its kind, have quantitatively demonstrated this link using responses from more than 10,000 people with T2D across 26 countries.(1,2)

Amgen (NASDAQ:AMGN) and Dezima Pharma B.V. (Dezima) today announced that the companies have entered into a definitive acquisition agreement under which Amgen will acquire Dezima, a privately-held, Netherlands-based biotechnology company focused on developing innovative treatments for dyslipidemia. Dezima shareholders have approved the agreement.

Amgen (NASDAQ:AMGN) and Xencor, Inc. (Xencor) (NASDAQ:XNCR) announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation. The research collaboration brings together Amgen's capabilities in target discovery and protein therapeutics with Xencor's XmAb® bispecific technology platform.

The Bayer Science & Education Foundation is making available approximately EUR 332,000 for 70 talented young people who wish to realize international study and vocational training projects. The new scholarship recipients are students of the natural sciences, agriculture and medicine, as well those training to become science teachers or young people from skilled non-academic professions.

Johnson & Johnson (NYSE: JNJ) announced today that Crucell Holland B.V., one of its Janssen Pharmaceutical Companies, has been awarded $28.5 million from The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, to help accelerate the development of its investigational Ebola prime-boost vaccine regimen.